These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28717032)

  • 21. Enhanced safety and immunogenicity of a pneumococcal surface antigen A mutant whole-cell inactivated pneumococcal vaccine.
    David SC; Laan Z; Minhas V; Chen AY; Davies J; Hirst TR; McColl SR; Alsharifi M; Paton JC
    Immunol Cell Biol; 2019 Sep; 97(8):726-739. PubMed ID: 31050022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae.
    Miyaji EN; Dias WO; Gamberini M; Gebara VC; Schenkman RP; Wild J; Riedl P; Reimann J; Schirmbeck R; Leite LC
    Vaccine; 2001 Dec; 20(5-6):805-12. PubMed ID: 11738744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.
    Moreno AT; Oliveira ML; Ferreira DM; Ho PL; Darrieux M; Leite LC; Ferreira JM; Pimenta FC; Andrade AL; Miyaji EN
    Clin Vaccine Immunol; 2010 Mar; 17(3):439-46. PubMed ID: 20089795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.
    Arulanandam BP; Lynch JM; Briles DE; Hollingshead S; Metzger DW
    Infect Immun; 2001 Nov; 69(11):6718-24. PubMed ID: 11598043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal vaccination with γ-irradiated Streptococcus pneumoniae whole-cell vaccine provides serotype-independent protection mediated by B-cells and innate IL-17 responses.
    Babb R; Chen A; Hirst TR; Kara EE; McColl SR; Ogunniyi AD; Paton JC; Alsharifi M
    Clin Sci (Lond); 2016 May; 130(9):697-710. PubMed ID: 26831937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.
    Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH
    Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen.
    Park SM; Ko HJ; Shim DH; Yang JY; Park YH; Curtiss R; Kweon MN
    J Immunol; 2008 Nov; 181(9):6447-55. PubMed ID: 18941235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Th17 responses to pneumococcus in blood and adenoidal cells in children.
    Oliver E; Pope C; Clarke E; Langton Hewer C; Ogunniyi AD; Paton JC; Mitchell T; Malley R; Finn A
    Clin Exp Immunol; 2019 Feb; 195(2):213-225. PubMed ID: 30325010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants.
    Malekan M; Siadat SD; Aghasadeghi M; Shahrokhi N; Afrough P; Behrouzi A; Ahmadi K; Mousavi SF
    J Med Microbiol; 2020 Mar; 69(3):465-477. PubMed ID: 32100705
    [No Abstract]   [Full Text] [Related]  

  • 31. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines.
    Converso TR; Goulart C; Rodriguez D; Darrieux M; Leite LCC
    Microb Pathog; 2017 Aug; 109():233-238. PubMed ID: 28602840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection against pneumococcal infection elicited by immunization with multiple pneumococcal heat shock proteins.
    Cao J; Zhang X; Gong Y; Zhang Y; Cui Y; Lai X; Yin Y; Li M; Li D; Zhang L
    Vaccine; 2013 Aug; 31(35):3564-71. PubMed ID: 23727004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country.
    Lundgren A; Bhuiyan TR; Novak D; Kaim J; Reske A; Lu YJ; Qadri F; Malley R
    Vaccine; 2012 Jun; 30(26):3897-907. PubMed ID: 22504663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
    Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
    PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
    Moore QC; Bosarge JR; Quin LR; McDaniel LS
    Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
    Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
    Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.